Prospective evidence for conversational medical AI: hard, but non-negotiable

The article's central thesis is that trust in clinical AI cannot be established through benchmarking and must instead be earned via rigorous prospective studies in real-world clinical settings. Relative to the common practice of measuring model capability by benchmark scores, this piece shifts the evaluation focus from model leaderboards to prospective validation in real clinical scenarios. This is an opinion-based claim stated in a single explicit assertion, accompanied by Fig. 1 'Building trust in conversational and reasoning clinical AI'; the body text sits behind a subscription wall, so its argumentation cannot be verified.

The article emphasizes that the hardest lessons in prospective studies often concern the humans and systems around the AI, not the technology itself. It extends attention from algorithmic performance to integration issues at the level of clinical workflows, personnel, and systems. This is a judgment offered by the authors based on their research experience, phrased as 'the hardest lessons often concern the humans and systems around the AI, not the technology itself', with no specific case data visible in the loaded text.

The article situates its discussion of the evidence landscape for conversational and reasoning clinical AI by citing a series of recent studies, including work in Science, Nature, Nature Medicine, and preprints. It places the article's argument within a literature context spanning multiple related studies from 2024 to 2026. The reference list shows citations to Brodeur et al. (Science 2026), Tu et al. (Nature 2025), Liévin et al. (Nature 2026), Saab et al. (Nat. Med. 2026), and others, but the visible text does not elaborate on each study's specific findings.

This is a comment article intended to set the tone for evidence standards in conversational and reasoning clinical AI, aimed at researchers, clinicians, and policymakers concerned with clinical AI evaluation methods. It suggests that subsequent work should treat prospective, real-world clinical studies as the path to building trust rather than stopping at the benchmark level.

Because only the comment's abstract, figure caption, and reference list were loaded, the body argumentation, the specific findings of the cited studies, and the details of Fig. 1 are not presented, so it is not possible to judge how the authors concretely develop the argument about 'where prospective studies are hard'. Readers interested in actionable study designs or specific evidence should consult the original article and its cited references.